Products & Services · Product revenues, net
Collaborativeand Royalty — Product revenues, net
Over 4 years (FY 2021 to FY 2025), Collaborativeand Royalty — Product revenues, net shows an upward trend with a 135.4% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
StatementSegment
CategoryGrowth
SignalHigher is better
VolatilityModerate
First reportedQ1 2016
Last reportedQ4 2025
Rolls up toTotal Revenue
How to read this metric
An increase suggests successful commercialization of new therapeutic assets or expansion into secondary markets, while a decrease may indicate lower-than-expected adoption of non-core products.
Detailed definition
This metric represents net product sales generated from secondary or emerging business segments outside of the company's...
Peer comparison
Peers in the biotechnology sector often report similar metrics as 'Other Product Revenue' or 'Emerging Franchise Revenue' to track the diversification of their commercial portfolios.
Metric ID:
vrtx_segment_other_revenues_product_revenues_netHistorical Data
19 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $10.00M | $20.70M | $0.00 | $0.00 |
| QoQ Change | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | +107.0% | -100.0% | — |
Range$0.00 – $20.70M
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Vertex Pharmaceuticals's collaborativeand royalty — product revenues, net?
- Vertex Pharmaceuticals (VRTX) reported collaborativeand royalty — product revenues, net of $0.00 in Q4 2025.
- What is the long-term trend for Vertex Pharmaceuticals's collaborativeand royalty — product revenues, net?
- Over 4 years (2021 to 2025), Vertex Pharmaceuticals's collaborativeand royalty — product revenues, net has grown at a 135.4% compound annual growth rate (CAGR), from $1.00M to $30.70M.
- What does collaborativeand royalty — product revenues, net mean?
- Net revenue generated from the sale of products within the company's secondary or emerging business segments.